These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo. Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959 [TBL] [Abstract][Full Text] [Related]
27. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Bhola NE; Freilino ML; Joyce SC; Sen M; Thomas SM; Sahu A; Cassell A; Chen CS; Grandis JR Mol Cancer Ther; 2012 Jun; 11(6):1236-46. PubMed ID: 22491800 [TBL] [Abstract][Full Text] [Related]
28. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. López-Albaitero A; Lee SC; Morgan S; Grandis JR; Gooding WE; Ferrone S; Ferris RL Cancer Immunol Immunother; 2009 Nov; 58(11):1853-64. PubMed ID: 19319529 [TBL] [Abstract][Full Text] [Related]
30. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Bozec A; Etienne-Grimaldi MC; Fischel JL; Sudaka A; Toussan N; Formento P; Milano G Oral Oncol; 2011 May; 47(5):340-4. PubMed ID: 21421338 [TBL] [Abstract][Full Text] [Related]
31. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227 [TBL] [Abstract][Full Text] [Related]
32. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc. Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and preclinical investigation of Shah SQ; Gul-E-Raana Mol Biol Rep; 2019 Apr; 46(2):1675-1682. PubMed ID: 30680596 [TBL] [Abstract][Full Text] [Related]
34. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines. De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149 [TBL] [Abstract][Full Text] [Related]
35. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779 [TBL] [Abstract][Full Text] [Related]
36. Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma. Espinosa-Cotton M; Rodman Iii SN; Ross KA; Jensen IJ; Sangodeyi-Miller K; McLaren AJ; Dahl RA; Gibson-Corley KN; Koch AT; Fu YX; Badovinac VP; Laux D; Narasimhan B; Simons AL J Immunother Cancer; 2019 Mar; 7(1):79. PubMed ID: 30890189 [TBL] [Abstract][Full Text] [Related]
37. The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Burtness B Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785 [TBL] [Abstract][Full Text] [Related]
38. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus. Zaoui K; Bossow S; Grossardt C; Leber MF; Springfeld C; Plinkert PK; Kalle Cv; Ungerechts G Cancer Gene Ther; 2012 Mar; 19(3):181-91. PubMed ID: 22076043 [TBL] [Abstract][Full Text] [Related]
39. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Sen M; Joyce S; Panahandeh M; Li C; Thomas SM; Maxwell J; Wang L; Gooding WE; Johnson DE; Grandis JR Clin Cancer Res; 2012 Sep; 18(18):4986-96. PubMed ID: 22825581 [TBL] [Abstract][Full Text] [Related]
40. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma. Okuyama K; Naruse T; Yanamoto S J Exp Clin Cancer Res; 2023 May; 42(1):114. PubMed ID: 37143088 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]